Literature DB >> 24850788

HIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment.

Katherine Luzuriaga1, Barbara Tabak2, Manuel Garber2, Ya Hui Chen3, Carrie Ziemniak3, Margaret M McManus4, Danielle Murray5, Matthew C Strain6, Douglas D Richman6, Tae-Wook Chun5, Coleen K Cunningham7, Deborah Persaud3.   

Abstract

BACKGROUND: Early initiation of combination antiretroviral therapy (cART) to human immunodeficiency virus type 1 (HIV-1)-infected infants controls HIV-1 replication and reduces mortality.
METHODS: Plasma viremia (lower limit of detection, <2 copies/mL), T-cell activation, HIV-1-specific immune responses, and the persistence of cells carrying replication-competent virus were quantified during long-term effective combination antiretroviral therapy (cART) in 4 perinatally HIV-1-infected youth who received treatment early (the ET group) and 4 who received treatment late (the LT group). Decay in peripheral blood mononuclear cell (PBMC) proviral DNA levels was also measured over time in the ET youth.
RESULTS: Plasma viremia was not detected in any ET youth but was detected in all LT youth (median, 8 copies/mL; P = .03). PBMC proviral load was significantly lower in ET youth (median, 7 copies per million PBMCs) than in LT youth (median, 181 copies; P = .03). Replication-competent virus was recovered from all LT youth but only 1 ET youth. Decay in proviral DNA was noted in all 4 ET youth in association with limited T-cell activation and with absent to minimal HIV-1-specific immune responses.
CONCLUSIONS: Initiation of early effective cART during infancy significantly limits circulating levels of proviral and replication-competent HIV-1 and promotes continuous decay of viral reservoirs. Continued cART with reduction in HIV-1 reservoirs over time may facilitate HIV-1 eradication strategies.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  continuous HIV-1 decay; early antiretroviral therapy; prolonged viral suppression; proviral reservoirs; reduced HIV reservoirs

Mesh:

Substances:

Year:  2014        PMID: 24850788      PMCID: PMC4215073          DOI: 10.1093/infdis/jiu297

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  33 in total

1.  Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection.

Authors:  Nancie M Archin; Naveen K Vaidya; Joann D Kuruc; Abigail L Liberty; Ann Wiegand; Mary F Kearney; Myron S Cohen; John M Coffin; Ronald J Bosch; Cynthia L Gay; Joseph J Eron; David M Margolis; Alan S Perelson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-29       Impact factor: 11.205

2.  Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy.

Authors:  Tae-Wook Chun; Danielle Murray; J Shawn Justement; Claire W Hallahan; Susan Moir; Colin Kovacs; Anthony S Fauci
Journal:  J Infect Dis       Date:  2011-07-01       Impact factor: 5.226

3.  Dynamics of the resting CD4(+) T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age.

Authors:  Deborah Persaud; Paul E Palumbo; Carrie Ziemniak; Michael D Hughes; Carmelita G Alvero; Katherine Luzuriaga; Ram Yogev; Edmund V Capparelli; Ellen G Chadwick
Journal:  AIDS       Date:  2012-07-31       Impact factor: 4.177

4.  Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication.

Authors:  Tae-Wook Chun; J Shawn Justement; Danielle Murray; Claire W Hallahan; Janine Maenza; Ann C Collier; Prameet M Sheth; Rupert Kaul; Mario Ostrowski; Susan Moir; Colin Kovacs; Anthony S Fauci
Journal:  AIDS       Date:  2010-11-27       Impact factor: 4.177

5.  Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers.

Authors:  B Julg; F Pereyra; M J Buzón; A Piechocka-Trocha; M J Clark; B M Baker; J Lian; T Miura; J Martinez-Picado; M M Addo; B D Walker
Journal:  Clin Infect Dis       Date:  2010-07-15       Impact factor: 9.079

6.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

7.  Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection.

Authors:  Jintanat Ananworanich; Alexandra Schuetz; Claire Vandergeeten; Irini Sereti; Mark de Souza; Rungsun Rerknimitr; Robin Dewar; Mary Marovich; Frits van Griensven; Rafick Sekaly; Suteeraporn Pinyakorn; Nittaya Phanuphak; Rapee Trichavaroj; Wiriya Rutvisuttinunt; Nitiya Chomchey; Robert Paris; Sheila Peel; Victor Valcour; Frank Maldarelli; Nicolas Chomont; Nelson Michael; Praphan Phanuphak; Jerome H Kim
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240

8.  Highly precise measurement of HIV DNA by droplet digital PCR.

Authors:  Matthew C Strain; Steven M Lada; Tiffany Luong; Steffney E Rought; Sara Gianella; Valeri H Terry; Celsa A Spina; Christopher H Woelk; Douglas D Richman
Journal:  PLoS One       Date:  2013-04-03       Impact factor: 3.240

9.  Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies.

Authors:  Susanne Eriksson; Erin H Graf; Viktor Dahl; Matthew C Strain; Steven A Yukl; Elena S Lysenko; Ronald J Bosch; Jun Lai; Stanley Chioma; Fatemeh Emad; Mohamed Abdel-Mohsen; Rebecca Hoh; Frederick Hecht; Peter Hunt; Ma Somsouk; Joseph Wong; Rowena Johnston; Robert F Siliciano; Douglas D Richman; Una O'Doherty; Sarah Palmer; Steven G Deeks; Janet D Siliciano
Journal:  PLoS Pathog       Date:  2013-02-14       Impact factor: 6.823

10.  Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study.

Authors:  Asier Sáez-Cirión; Charline Bacchus; Laurent Hocqueloux; Véronique Avettand-Fenoel; Isabelle Girault; Camille Lecuroux; Valerie Potard; Pierre Versmisse; Adeline Melard; Thierry Prazuck; Benjamin Descours; Julien Guergnon; Jean-Paul Viard; Faroudy Boufassa; Olivier Lambotte; Cécile Goujard; Laurence Meyer; Dominique Costagliola; Alain Venet; Gianfranco Pancino; Brigitte Autran; Christine Rouzioux
Journal:  PLoS Pathog       Date:  2013-03-14       Impact factor: 6.823

View more
  69 in total

1.  Young age at start of antiretroviral therapy and negative HIV antibody results in HIV-infected children when suppressed.

Authors:  Louise Kuhn; Diana B Schramm; Stephanie Shiau; Renate Strehlau; Francoise Pinillos; Karl Technau; Ashraf Coovadia; Elaine J Abrams; Adrian Puren; Caroline T Tiemessen
Journal:  AIDS       Date:  2015-06-01       Impact factor: 4.177

Review 2.  Pediatric HIV: the Potential of Immune Therapeutics to Achieve Viral Remission and Functional Cure.

Authors:  Stella J Berendam; Ashley N Nelson; Ria Goswami; Deborah Persaud; Nancy L Haigwood; Ann Chahroudi; Genevieve G Fouda; Sallie R Permar
Journal:  Curr HIV/AIDS Rep       Date:  2020-06       Impact factor: 5.071

3.  Xpert HIV-1 point-of-care test for neonatal diagnosis of HIV in the birth testing programme of a maternity hospital: a field evaluation study.

Authors:  Karl-Günter Technau; Louise Kuhn; Ashraf Coovadia; Pamela M Murnane; Gayle Sherman
Journal:  Lancet HIV       Date:  2017-07-12       Impact factor: 12.767

4.  Early and Highly Suppressive Antiretroviral Therapy Are Main Factors Associated With Low Viral Reservoir in European Perinatally HIV-Infected Children.

Authors:  Alfredo Tagarro; Man Chan; Paola Zangari; Bridget Ferns; Caroline Foster; Anita De Rossi; Eleni Nastouli; María A Muñoz-Fernández; Diana Gibb; Paolo Rossi; Carlo Giaquinto; Abdel Babiker; Claudia Fortuny; Riccardo Freguja; Nicola Cotugno; Ali Judd; Antoni Noguera-Julian; María Luisa Navarro; María José Mellado; Nigel Klein; Paolo Palma; Pablo Rojo
Journal:  J Acquir Immune Defic Syndr       Date:  2018-10-01       Impact factor: 3.731

5.  Delayed HIV detection among infants exposed to postnatal antiretroviral prophylaxis during breastfeeding.

Authors:  Caroline C King; Athena P Kourtis; Deborah Persaud; Julie A E Nelson; Carrie Ziemniak; Michael G Hudgens; Gerald Tegha; Charles S Chasela; Denise J Jamieson; Charles M van der Horst
Journal:  AIDS       Date:  2015-09-24       Impact factor: 4.177

Review 6.  Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications.

Authors:  Véronique Avettand-Fènoël; Laurent Hocqueloux; Jade Ghosn; Antoine Cheret; Pierre Frange; Adeline Melard; Jean-Paul Viard; Christine Rouzioux
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

7.  Early age at start of antiretroviral therapy associated with better virologic control after initial suppression in HIV-infected infants.

Authors:  Stephanie Shiau; Renate Strehlau; Karl-Günter Technau; Faeezah Patel; Stephen M Arpadi; Ashraf Coovadia; Elaine J Abrams; Louise Kuhn
Journal:  AIDS       Date:  2017-01-28       Impact factor: 4.177

Review 8.  Very early combination antiretroviral therapy in infants: prospects for cure.

Authors:  Kaitlin Rainwater-Lovett; Katherine Luzuriaga; Deborah Persaud
Journal:  Curr Opin HIV AIDS       Date:  2015-01       Impact factor: 4.283

Review 9.  Infectious Diseases of Poverty in Children: A Tale of Two Worlds.

Authors:  Caitlin Hansen; Elijah Paintsil
Journal:  Pediatr Clin North Am       Date:  2016-02       Impact factor: 3.278

Review 10.  Paediatric HIV infection: the potential for cure.

Authors:  Philip J Goulder; Sharon R Lewin; Ellen M Leitman
Journal:  Nat Rev Immunol       Date:  2016-03-14       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.